Business Wire

GENEXINE

Share
Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that GX-188E, its first-in-class proprietary DNA vaccine, demonstrated potent efficacy and favorable safety in patients with advanced cervical cancer in a phase 2 study when given in combination with KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy.

A total of 60 patients with HPV 16- and/or 18- positive advanced cervical cancer were analyzed in the phase 2 treatment group. Top line results showed a Best Overall Response Rate (BORR) of 31.7% (19 of 60 patients). 6 patients (10.0%) had a complete response and 13 patients (21.7%) had a partial response. Median duration of response (DOR) was 12.3 months and overall survival (OS) was 17.2 months.

The BORR increased to 38.5% in PD-L1 positive patients with HPV 16+ and Squamous Cell Carcinoma. Importantly, PD-L1 negative patients showed an ORR of 25.0%, which is extremely encouraging for this patient population, as it demonstrates potential improvement in efficacy compared to monotherapy of immune checkpoint inhibitors, suggesting a beneficial effect of the combination therapy.

In the safety analysis (n=65) 22 of 65 patients (33.8%) had treatment-related adverse events (TRAEs) of any grade and three (4.6%) had grade 3 or 4 TRAEs. The combination therapy was found to be safe and tolerable with a similar safety profile to that of pembrolizumab monotherapy.

“There is an urgent need for better therapies for patients with advanced cervical cancer and the combination of a therapeutic DNA vaccine together with checkpoint inhibition could be a strong alternative,” said professor Sung-Jong Lee of the Catholic University of Korea, College of Medicine and Investigator in the trial. “The data are very encouraging and appear to show a clear efficacy signal and the product appears safe and well tolerated. I am particularly pleased to see a clear efficacy signal in all patients, regardless of PD-L1 expression. Genexine’s combination therapy has strong appeal from a mechanistic perspective. This approach of using checkpoint inhibition to restore immune system function combined with the vaccine’s effect of upregulating and increasing the influx of CD8+ and other immune cells into the tumor microenvironment, appears to result in a strong, beneficial effect as demonstrated by major outcome measures such as BORR (31.7%) and OS (17.2 months) through the elimination of tumor cells and tumors.”

“We are very pleased to have been invited to present our phase 2 top-line data at ESMO and encouraged by the efficacy and safety shown in this study,” said Neil Warma, President and CEO of Genexine. “The combination of GX-188E, our unique DNA vaccine, with pembrolizumab could represent a new standard of care for patients with HPV 16/18 related recurrent or metastatic cervical cancer, regardless of PD-L1 expression. We are encouraged by the ORR of over 31% but particularly excited by the efficacy signal observed in PD-L1 negative patients. This could open the door to a new therapy for this patient population that previously had limited treatment options available.”

The clinical trial was an open-label, single-arm, phase 2 trial conducted in South Korea in patients with HPV-16 or HPV-18 positive advanced cervical cancer, and who had progressed after standard-of-care therapy. Patients received intramuscular 2 mg GX-188E at weeks 1, 2, 4, 7, 13, 19, and optional dose at week 46, and intravenous pembrolizumab 200 mg every 3 weeks for up to 2 years or until disease progression. The primary endpoint was ORR assessed by the blinded independent central reviewers (BICR) using RECIST version 1.1.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ.

About Genexine

Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Primary technology platforms are Therapeutic DNA vaccine technology and hyFc® fusion technology. The company has multiple products in clinical development, including several undergoing phase 3 registration trials. The company's proprietary pipeline includes GX-188E for cervical cancer and head and neck cancer, GX-I7 (efineptakin alfa) for multiple cancers, GX-H9 (eftansomatropin alfa) for Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean stock exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide.

About GX-188E

GX-188E is a novel DNA-based therapeutic vaccine discovered by Genexine and being jointly developed with the National Cancer Center Korea Onco-Innovation Unit (NOIU). It has a mechanism of inducing an antigen-specific T-cell immune response to E6/E7, a cancer-causing protein produced by HPV types 16 and 18, which are the main causes of cervical cancer. The T cells with activated immune response have an immune-anticancer mechanism that effectively eliminates cervical cancer cells by inducing a cytotoxic T lymphocyte response. Genexine is currently developing GX-188E in cervical cancer and is also conducting two on-going combination trials with GX-188E in Squamous Cell Carcinoma of the Head and Neck (SCCHN).

About Cervical Cancer

Cervical cancer is a cancer arising from the cervix and is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Human Papilloma Virus (HPV) causes more than 90% of cases and HPV 16 and 18 strains are responsible for the majority of high grade cervical cancers. According to WHO, cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. A recent Arizton research report estimated that the cervical cancer therapeutics market was $5.5 billion in 2021 and expected to grow at a CAGR of 4.14% during 2021-2027 to reach $7.1 billion with targeted therapies expected to be the fastest-growing segment during the forecast period.

Forward Looking Statements

This press release contains forward-looking statements regarding the business of Genexine, Inc. ("Genexine"). Any statement describing Genexine's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Genexine's drug development pipeline, including without limitation GX-I7 (efineptakin alfa), GX-188E, GX-H9 (eftansomatropin alfa), GX-E4 is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs.

Genexine's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Genexine's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Genexine. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Genexine's programs are described in additional detail in Genexine's annual reports on DART (Data Analysis, Retrieval and Transfer System) internet site (https://dart.fss.or.kr/) of the Korean Financial Supervisory Service. Genexine assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907006295/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vantage Data Centers Expands European Footprint with Second Italian Campus15.10.2025 14:00:00 CEST | Press release

State-of-the-art, sustainable Milan campus to deliver 32MW of IT capacity for digital transformation; company’s developments recognized by the Italian government as national strategic investments Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced the expansion of its Italian footprint to include a second campus in Milan. With an investment of more than €350 million (approximately $407 million USD), the MXP2 campus is designed to support the growing demand for high-performance, scalable digital infrastructure in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015151520/en/ Vantage Data Centers’ growing Italian footprint includes a second Milan campus with 32MW of IT capacity. Located in Castelletto just 15 kilometers (less than 10 miles) from central Milan, the campus will feature two modern data centers delivering a combined 32MW of critical IT capacity across a

NetApp and the 49ers Foundation Launch Data Science Education Partnership15.10.2025 14:00:00 CEST | Press release

Multi-year initiative aims to empower students with hands-on tech learning at Levi’s® Stadium NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and the 49ers Foundation, the largest team foundation in the NFL, today announced a multi-year partnership to provide data science education to high school students in the San Francisco Bay Area. The 49ers EDU Data Analytics Lessons Series seeks to inspire and equip the next generation of tech leaders with essential skills in data science and introduce students to career opportunities in technology. The partnership will enable NetApp and the 49ers Foundation to utilize the unique setting of Levi’s® Stadium to provide immersive educational experiences. This collaboration is part of the 49ers EDU STEAM education program and builds upon its impactful history of educating over a half a million students in the Bay Area and beyond through digital and in-person programming. 49ers EDU educators will lead all lessons part of the Data

Merck to Acquire the Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio15.10.2025 14:00:00 CEST | Press release

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutionsJSR’s innovative Amsphere™ Protein A resin technology complements Merck’s existing biologics portfolioEnhances Merck’s capabilities to accelerate next-generation therapies by optimizing antibody purification Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition will expand Merck’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. The transaction is expected to close by the end of the second quarter of 2026. This press release features multimedia. View the full release her

‘Warmer Together’: Moncler Celebrates Warmth and Love, With Legendary Friends Al Pacino and Robert De Niro15.10.2025 14:00:00 CEST | Press release

Moncler’s new campaign reunites two lifelong friends and icons of Hollywood for a cinematic expression of friendship, connection, and human warmth. Over seven extraordinary decades of evolution and innovation, Moncler has become synonymous with warmth, embracing the elements, and year-round performance and style. It’s true the brand was born in the Alps in 1952 with a mission to protect climbers and mountain workers from the extreme cold, but for Moncler, warmth was never about the outside. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015925807/en/ Al Pacino and Robert De Niro star in Moncler’s Warmer Together campaign. Courtesy of Moncler To manifest that essence, Moncler today unveils the new global statement, Warmer Together, bringing Al Pacino and Robert De Niro together for their first-ever shared campaign. Warmer Together goes beyond words, it is the heartbeat of Moncler’s purpose. From the very beginning, the bra

Josh Krichefski Joins PMG as EMEA President15.10.2025 13:00:00 CEST | Press release

Former WPP executive to lead and accelerate growth across PMG’s EMEA operations. PMG, a global independent marketing services and technology company, today announced the appointment of Josh Krichefski to EMEA President, effective October 20th. In this new role, Krichefski will lead the strategy and expansion of PMG’s operations across the region, with a focus on scaling growth and driving excellence in customer delivery. He will oversee all aspects of the EMEA business, including commercial performance, talent development, and the introduction of new capabilities and partnerships aligned to PMG’s global vision. Krichefskiwill be based in PMG’s London office and will partner directly with George Popstefanov, Founder & CEO and Jon Dupuis, Global President. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015978859/en/ Josh Krichefski Dupuis commented: “Josh’s appointment marks an exciting next chapter in our EMEA growth. With

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye